

1 NOAH T. KATZEN  
2 Trial Attorney  
3 Consumer Protection Branch  
4 U.S. Department of Justice  
5 P.O. Box 386  
6 Washington, DC 20044-0386  
7 (202) 305-2428  
8 (202) 514-8742 (fax)  
9 Noah.T.Katzen@usdoj.gov

10  
11 UNITED STATES DISTRICT COURT  
12 FOR THE EASTERN DISTRICT OF WASHINGTON  
13

14 STATE OF WASHINGTON, *et al.*,

No. 1:23-cv-03026

15 Plaintiffs,

NOTICE OF SUPPLEMENTAL  
INFORMATION

16 v.

17 U.S. FOOD AND DRUG  
ADMINISTRATION, *et al.*,

Defendants.

18  
19 On March 28, 2023, this Court held oral argument on Plaintiff States’  
20 Motion for Preliminary Injunction. ECF Dkt. 70. During the argument, the Court  
21 asked counsel for Defendants whether any drugs other than Mifeprex  
22 (mifepristone) are subject to a Risk Evaluation and Mitigation Strategy (REMS)  
23 that includes a pharmacy certification requirement. *See* 21 U.S.C. § 355-1(f)(3)(B).  
24 Upon further review of the REMS for approved drugs and biological products  
25  
26

1 posted on FDA’s website,<sup>1</sup> Defendants have determined that more than three dozen  
2 other new drug application (NDA) or biologics license application (BLA) products  
3  
4 (not including abbreviated new drug application (ANDA) products, *i.e.*,  
5 “generics”) are subject to a REMS that includes a pharmacy certification  
6 requirement: Letairis (ambrisentan), Tracleer (bosentan), Camzyos (mavacamtem),  
7  
8 Caprelsa (vandetanib), Clozaril (clozapine), Fazaclo ODT (clozapine), Versacloz  
9 (clozapine), Empaveli (pegcetacoplan), Filspari (sparsentan), Fintepla  
10 (fenfluramine hydrochloride), Absorica (isotretinoin), Absorica LD (isotretinoin),  
11  
12 Juxtapid (lomitapide), Jynarque (tolvaptan), Lemtrada (alemtuzumab), Revlimid  
13 (lenalidomide), Opsumit (macitentan), Myalept (metrepleptin), Natpara  
14 (parathyroid hormone), Palforzia (peanut (*Arachis hyogaea*) allergen powder-  
15  
16 dnfp), Palynziq (pegvaliase-pqpz), Pomalyst (pomalidomide), Probuphine  
17 (buprenorphine hydrochloride), Qsymia (phentermine and topiramate), Adempas  
18 (riociguat), Siliq (brodalumab), Spravato (esketamine), Sublocade (buprenorphine  
19 extended-release), Tecvalyi (teclistamab-cqyv), Tegsedi (inotersen), Thalomid  
20 (thalidomide), Actiq (fentanyl citrate), Fentora (fentanyl citrate), Lazanda (fentanyl  
21 citrate), Onsolis (fentanyl citrate), Subsys (fentanyl), Turalio (pexdartinib), Tysabri  
22 (natalizumab), Sabril (vigabatrin), Xiaflex (collagenase clostridium histolyticum)  
23  
24

---

25  
26 <sup>1</sup> <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm>

1 (for the Peyronie’s disease indication), Xyrem/Xywav (calcium, magnesium,  
2 potassium, and sodium oxybates), Zulresso (brexanolone), and Zyprexa Relprevv  
3  
4 (olanzapine).

5 March 29, 2023

HILARY K. PERKINS  
Assistant Director

7  
8 /s/ Noah T. Katzen  
9 NOAH T. KATZEN  
10 Trial Attorney  
11 Consumer Protection Branch  
12 U.S. Department of Justice  
13 P.O. Box 386  
14 Washington, DC 20044-0386  
15 (202) 305-2428  
16 (202) 514-8742 (fax)  
17 Noah.T.Katzen@usdoj.gov

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
*Counsel for Defendants*

**CERTIFICATE OF SERVICE**

I hereby certify that, on March 29, 2023, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF system, which will send notification of such filing to all counsel of record.

/s/ Noah T. Katzen  
NOAH T. KATZEN